From the April 2017 issue of HealthCare Business News magazine
For the large number of patients who undergo major cardiac surgery in the U.S. and around the world each year, better therapies are needed to lower the risk of serious postoperative complications. These various strategies, that use different methods to counter inflammation, are likely to act in synergy. This could pave the way for safer and more predictable clinical outcomes in complex cardiac surgery that is anything but routine.
About the author: Dr. Phillip P. Chan, M.D., Ph.D., is chief executive officer and president of CytoSorbents Corporation.Back to HCB News
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.